The second IU Grand Challenges webinar about the Precision Health Initiative (PHI) took place this month, focusing on progress in studying and treating childhood sarcomas, which are cancers that develop in the bones and soft tissues. This webinar featured Jamie Renbarger, MD, and Karen Pollok, PhD, co-leaders of the IU Precision Health Initiative pediatric sarcomas disease research team, as well as Tatiana Foroud, PhD, who leads the IU Precision Health Initiative. Kelly and Tony Trent, parents of the late Tyler Trent, also joined the conversation to share Tyler’s journey of fighting osteosarcoma, an aggressive form of bone cancer. IU Vice President for Research Fred Cate served as the event’s host.
Precision Health News
In the last month, the IU Precision Health Initiative researchers have been in the news talking about topics such as when we can declare the COVID-19 pandemic over, children with cardiomyopathy and genetic screenings, stigma about mental illness and mass violence, type 2 diabetes, COVID-19 long haulers, and more.
In the last month, the IU Precision Health Initiative has been in the news for several different projects, such as COVID-19 Long Haulers, the importance of medical informatics amid the pandemic, sharing goals for the new IU Simon Comprehensive Cancer Center leader, and more.
At the virtual 2021 IU Precision Health Initiative retreat, key leaders from the scientific pillars and disease research teams were present to talk about plans to sustain the success of the initiative after the first five years of the program end in August of this year. The IU Precision Health Initiative was the first Grand Challenge announced by Indiana University back in 2016. Since then, 55 new faculty members have been hired, as well as 117 nontenured employees. More than 820 peer-reviewed studies have been published and more than $89 million in grant funding has been awarded. The initiative has also created more than 350 new jobs.
In the last month, the IU Precision Health Initiative has been in the news for several different projects, such as ways to plan for a safe spring break, the MaskCount app, COVID-19 Long Haulers, triple negative breast cancer research, and more.
More than 120 people participated in the first IU Grand Challenges webinar about the Precision Health Initiative. The theme of this event was progress in triple negative breast cancer, featuring Bryan Schneider, MD, and Milan Radovich, PhD, co-leaders of the IU Precision Health Initiative triple negative breast cancer disease research team, as well as breast cancer survivor Meredith McMahan who is also a practice administrator at IU Health. Tatiana Foroud, PhD, who leads the IU Precision Health Initiative, was a featured panelist, with IU Vice President for Research Fred Cate serving as the host.
In the last month, the IU Precision Health Initiative has been in the news for several different projects, such as immunity to COVID-19, vaccine development, disparities during the pandemic, kidney research, COVID-19 Long Haulers, and more.
Researchers at IU School of Medicine have developed a promising combination drug therapy for triple negative breast cancer that was shown to be safe and well-tolerated in early-stage studies. Milan Radovich, PhD, and his colleagues tested a combination of two drugs — gedatolisib (an experimental small molecule) and cofetuzumab pelidotin (an experimental biologic) — as part of an initial safety study for triple negative breast cancer patients.
In the last couple months, the IU Precision Health Initiative has been in the news for several different projects, such as research about Tyler Trent's tumor cells, COVID statistics, the new Regenerative Medicine PhD program, COVID-19 Long Hauler research, and more.
Researchers at Indiana University School of Medicine have published their work about a specific type of childhood cancer in the peer-reviewed, international oncology journal, Cancers. This research involves a combination therapy that significantly slows tumor growth in models, which includes a model established from cells taken from tumors donated by Tyler Trent. This is the first published manuscript that includes Trent’s tumor model.